11,358 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 11,358 shares of the biopharmaceutical company’s stock, valued at approximately $8,091,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. GSA Capital Partners LLP acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $665,000. Empowered Funds LLC grew its holdings in Regeneron Pharmaceuticals by 7.1% during the third quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company’s stock worth $1,737,000 after acquiring an additional 109 shares during the period. Atlanta Consulting Group Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $534,000. Claro Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 110.6% during the third quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company’s stock worth $502,000 after acquiring an additional 251 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in Regeneron Pharmaceuticals by 16.7% during the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock worth $9,587,000 after acquiring an additional 1,306 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 1.7 %

Regeneron Pharmaceuticals stock opened at $678.42 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $74.17 billion, a P/E ratio of 17.72, a PEG ratio of 2.34 and a beta of 0.27. The stock has a 50-day simple moving average of $694.15 and a 200-day simple moving average of $827.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on REGN. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.